Scarica l'app Stockscreener
9.46
1.36%
-0.13
Pre-mercato:
9.47
0.010
+0.11%
Arvinas Inc Borsa (ARVN) Ultime notizie
What data driven models say about Arvinas Inc.’s futureJuly 2025 Catalysts & Weekly Momentum Picks - newser.com
How to forecast Arvinas Inc. trends using time seriesGap Down & Weekly High Potential Alerts - newser.com
What MACD signals say about Arvinas Inc.Earnings Miss & High Conviction Buy Zone Alerts - newser.com
Can Arvinas Inc. stock withstand economic slowdownJuly 2025 Selloffs & Verified Momentum Stock Ideas - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Is Arvinas Inc. trending in predictive chart models2025 Earnings Surprises & Low Risk Entry Point Guides - newser.com
Full technical analysis of Arvinas Inc. stockTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook By Investing.com - Investing.com South Africa
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook - Investing.com
Arvinas Holding Company (ARVN) Receives a Hold from Bank of America Securities - The Globe and Mail
Piper Sandler raises Arvinas stock price target to $16 on LRRK2 degrader data - Investing.com
Arvinas Announces Positive Phase 1 Trial Results - TipRanks
Arvinas Says Potential Parkinson's Disease Treatment Well Tolerated in Early Trials; Shares Gain Pre-Bell - MarketScreener
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Top Companies in Targeted Protein Degradation MarketBristol - openPR.com
Is Arvinas Inc. reversing from oversold territoryShort Setup & Weekly Chart Analysis and Guides - newser.com
Full Stock Market News from 2025-10-05 - Stock Titan
Arvinas (ARVN) Highlights Promising Phase 1 Trial Results for AR - GuruFocus
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials By Investing.com - Investing.com Nigeria
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials - Investing.com India
Arvinas, Inc. Reports Positive Phase 1 Trial Results for ARV-102 in Healthy Volunteers and Parkinson's Disease Patients - Quiver Quantitative
Arvinas Presents Late Breaking, Positive Phase 1 Clinical - GlobeNewswire
97% LRRK2 Reduction — Arvinas' ARV-102 Shows Strong PBMC Target Engagement and CSF Biomarker Modulation - Stock Titan
Will a bounce in Arvinas Inc. offer an exitJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - newser.com
Real time alert setup for Arvinas Inc. performanceJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is Arvinas Inc. stock poised for growthQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Tools to monitor Arvinas Inc. recovery probabilityWeekly Loss Report & Real-Time Volume Analysis - newser.com
Can Arvinas' Brain-Penetrant PROTAC Deliver On Its Promise In Parkinson's Trials? - RTTNews
Voya Investment Management LLC Has $124,000 Holdings in Arvinas, Inc. $ARVN - Defense World
Using fundamentals and technicals on Arvinas Inc.July 2025 Outlook & Safe Capital Preservation Plans - newser.com
Arvinas, Inc. to Present Clinical Data for Investigational PROTAC LRRK2 Degrader ARV-102 at MDS 2025 Conference - Quiver Quantitative
Arvinas to Present Clinical Data for ARV-102, a PROTAC - GlobeNewswire
First-Ever PROTAC LRRK2 Degrader Human Trial Data: Arvinas Reveals Breakthrough Parkinson's Results - Stock Titan
What drives Arvinas Inc stock priceTechnical Pattern Recognition & Low Risk Investment Portfolio - earlytimes.in
Arvinas, Inc. $ARVN Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Arvinas Announces 15% Workforce Reduction and Cost Savings - MSN
What analysts say about Arvinas Inc stockAnalyst Downgrades & Small Budget Capital Gain - earlytimes.in
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why The Narrative Around Arvinas Is Shifting After Recent Pipeline And Partnership Changes - Yahoo Finance
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):